Skip to main content
Fig. 4 | Molecular Brain

Fig. 4

From: Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation

Fig. 4

Rescue of elevated mTOR pathway activation by everolimus treatment. a Representative immunoblot of reduced S6K1 phosphorylation by everolimus treatment. b Mean phospho-S6K levels generated by TSC2 variants’ expression relative to wild-type TSC1-TSC2 expression in the presence of vehicle (DMSO) or everolimus (One-way ANOVA followed by Bonferroni’s test, ** p <0.01). All data are shown as the mean ± SEM of three independent experiments

Back to article page

Molecular Brain

ISSN: 1756-6606